Tripos Announces LeadScreen™ 2002, Pre-Formatted Screening Compound Set to Accelerate Drug Discovery by Biotechs

22-May-2002

News Highlights

- A novel "turnkey" screening solution for emerging biotech companies - Offers 50,000 novel, high purity compounds as a preformatted set - A proven source of viable leads in the search for new drugs against biological targets

St. Louis, MO - May 21, 2002 - Tripos, Inc. , a leading provider of drug discovery chemistry, software and services announced today the availability of LeadScreen™ 2002, the latest version of its novel, pre-formatted set of high throughput screening compounds. This product is intended to accelerate the discovery efforts of emerging biotechnology companies worldwide as they seek to identify drugs active against a variety of biological targets.

LeadScreen gives biotechnology customers economical access to high quality compounds from the highly-respected LeadQuest libraries. LeadQuest's informatics- driven design is based on Tripos' proprietary ChemSpace® technology, ensuring that compounds are novel, diverse and pharmaceutically relevant. Ready-to-ship and ready-to-use, LeadScreen compounds are high purity, pre-selected, and pre-formatted in 96-well plates to function as a "turnkey" solution for biotech customers. Once activity of a LeadScreen compound has been demonstrated in a bioassay, Tripos' design tools and rapid synthesis capabilities enable swift lead optimization using customized LeadFocus™ or LeadHopping™ libraries.

"LeadScreen compounds have proven to be a good source of viable leads with utility across a broad range of target areas," said Peter Hecht, Senior Vice President, Discovery Research and Operations, "The majority of LeadScreen customers have returned for re-supply of LeadScreen hits or rapid follow-up chemistry services such as LeadFocus libraries. Their experience confirms published findings showing that LeadQuest compounds increase the likelihood of finding bona fide lead candidates."

"Industry sources estimate that there are approximately 4,000 small or developing biotech companies in the world today," said Dr. Denise Beusen, Director of Technical Marketing at Tripos. "Many of them need rapid results from screening to secure additional funding or investor interest. Literally all these companies could benefit from a turnkey screening solution like LeadScreen."

https://www.bionity.com/en/news/10812/tripos-announces-leadscreen-2002-pre-formatted-screening-compound-set-to-accelerate-drug-discovery-by-biotechs.html